What Is a Clinical Trial Endpoint, and Why Is Endpoint Selection Crucial?

What Is a Clinical Trial Endpoint?

Before drug developers can claim that a drug effectively treats or cures a disease, they must provide clear, measurable evidence. Clinical trial endpoints are that evidence.

 
For instance, in ophthalmology:

• A drug for wet AMD must show improved visual acuity, such as more letters read on an eye chart.
• A structural biomarker like central subfield retinal thickness (measured via OCT) can also serve as an endpoint, provided it is measured consistently across devices.

As new therapeutic targets emerge, especially in ophthalmology, traditional endpoints like visual acuity are no longer sufficient. Conditions such as geographic atrophy and inherited retinal diseases require novel endpoints, which must undergo rigorous validation.

Why Is Endpoint Selection Crucial?

Since endpoints are the evidence of a drug’s efficacy and safety, proper selection is vitally important. Despite this, a recurring issue in clinical trial design is poor endpoint selection, which can undermine even the most well-executed trials.

Common pitfalls include:

• Use of endpoints with limited clinical significance, such as minor biomarker changes that do not translate into tangible patient benefits
• Reliance on surrogate endpoints that lack validation and are not recognized by regulatory authorities
• Inconsistencies with FDA guidance or misalignment with established real-world clinical practices

Selecting the right clinical trial endpoint is not just a regulatory requirement: it is the foundation of credible, actionable evidence in drug development. Especially in fields like ophthalmology, where emerging therapies target complex and previously untreatable conditions, the need for innovative, validated, and clinically meaningful endpoints has never been greater. By aligning endpoint selection with patient outcomes, regulatory expectations, and real-world clinical relevance, researchers can ensure that their trials not only meet approval standards but also deliver true value to patients.